News

Mr Mittelstadt began research in surgical robotics in 1986 as a visiting research scientist at the IBM TJ Watson Research Center and is responsible for much of the

This will be in combination with substantial investment on clinical research for generating India-specific data for both, new product development, and marketing existing products. The company plans to

The non-exclusive agreement provides Funakoshi with the rights to distribute in Japan. Among the Standardized RT-PCR reagents (StaRT-PCR) based research molecular tools are kits for chronic myelogenous leukemia,

Lyfetec and its management develop personal medical screening technology. Technologies and assets included in the contemplated acquisition include in-home test kits for the diagnosis and early detection of

These three trials will provide additional data on mipomersen in high-risk patient populations. The new studies, together with ongoing trials, will also substantially increase the size of the

The FDA considers the recommendations of its advisory committees when making its determinations. If approved, ATryn will be the first recombinant human antithrombin available in the US, said

This Phase IIb trial is a randomized, open-label, multi-center, active-controlled, adaptive-design dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every four weeks plus daily

The proof-of-concept trial in hepatitis C virus (HCV)-infected patients is being conducted at multiple centers around the world. The trial design is a Phase I/II, double-blind, placebo-controlled, dose-escalation

Under the terms of the commercialization agreement, Illumina will exclusively market, sell, distribute and service Base technology products developed by Oxford Nanopore for DNA sequencing into the research